SCHEMBL4457802

SCHEMBL4457802

CC(C(=O)O)C(=O)c1cc(F)cc(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.53
CES2 O00748 5/20 0.52
CES1 P23141 5/20 0.52
HCAR1 Q9BXC0 1/20 0.41
HCAR2 Q8TDS4 2/20 0.35
CHRNB2 P17787 1/20 0.35
SLC6A2 P23975 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
NR1I2 O75469 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
HCAR3 P49019 1/20 0.33
GRM5 P41594 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32
GRIA2 P42262 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRL1 P41146 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8310512 0.80 SLC6A3 (0.58) SLC6A3CES2CES1HCAR1HCAR2
SCHEMBL2379291 0.79 CES2 (0.48) SLC6A3CES2CES1SLC6A2CA1
SCHEMBL770101 0.77 SLC6A3 (0.55) SLC6A3CES2CES1HCAR1HCAR2
SCHEMBL4487448 0.76 LMNA (0.41) CES2CES1
SCHEMBL1226538 0.75 SLC6A3 (0.62) SLC6A3CES2CES1HCAR1HCAR2
SCHEMBL3305385 0.75 SLC6A3 (0.62) SLC6A3CES2CES1HCAR1HCAR2
SCHEMBL10762807 0.75 CHRNA1 (0.57) SLC6A3CES2CES1CHRNB2SLC6A2
SCHEMBL5163796 0.73 CES2 (0.50) SLC6A3CES2CES1NR1I2TRPM8
SCHEMBL5163803 0.73 CES2 (0.50) SLC6A3CES2CES1NR1I2TRPM8
SCHEMBL3550015 0.72 SLC6A3 (0.43) SLC6A3CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118223-A1 Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives MERCK SHARP & DOHME CORP. 2009-05-07 US disclosed
EP-1915053-A2 NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES Merck & Co., Inc. (US) 2008-04-30 EP disclosed
WO-2007022073-A2 NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES MERCK & CO., INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118223-A1 Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives MTAP, NT5C3B, NSUN2 SLC6A3 1452/4885CES2 299/4885CES1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.